arrow
S

Sneha Ramakrishna

Stanford University
H-index:21
Citation Count:5,034
Views:0

Biography

No content for now.

Education

No content for now.

Work Experience

No content for now.

Honors & Awards

No content for now.

Docetaxel-Induced Myositis in a 16-Year-Old Male With Rhabdomyosarcoma: Case Report and Literature Review

多西他赛诱导的16岁男性横纹肌肉瘤患者肌炎:病例报告及文献综述

2026-07-011
PRE
Expert Panel Review and Practical Guidance on Biomarker Testing With Engineered Immune Effector Cells

专家小组评审及工程化免疫效应细胞生物标志物检测的实用指南

2026-05-160
OAAI
Linking HLA-DRB1*15 to Severe Dress-like Inflammatory Toxicities Following Tocilizumab after CAR-T Therapy

将HLA-DRB1*15与托珠单抗治疗后的CAR-T疗法相关严重DRESS样炎症性毒性反应相联系

2026-03-100
PRE
Imaging the efficacy and side effects of CAR T-cell therapy in children and young adults

评估CAR T细胞疗法在儿童和年轻成人中的疗效和副作用

2026-02-120
PRE
The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer

CAR T细胞治疗在儿童、青少年和青年癌症患者中的典型作用

2026-01-230
PRE
EVALUATION OF B7-H3 IMMUNOHISTOCHEMISTRY IN HIGH-GRADE GLIOMAS FOR CHIMERIC ANTIGEN RECEPTOR T-CELL PREDICTIVE TESTING

B7-H3免疫组织化学在高级别胶质瘤中用于嵌合抗原受体T细胞预测性检测的评价

2025-11-010
OAAI
HUMANIZED ANTI-CAR ANTIBODIES AFFECT DURABLE RESPONSE TO GD2-CAR T-CELLS IN DIFFUSE MIDLINE GLIOMA

人源化抗CAR抗体影响弥漫性中线胶质瘤中GD2-CAR T细胞的持久应答

2025-11-010
OAAI
SINGLE-CELL LANDSCAPE OF B7H3-CAR T THERAPY IN GLIOMA: MECHANISMS OF RESISTANCE AND SIGNATURES OF LONG-TERM RESPONSE

单细胞景观揭示B7H3-CAR T疗法在胶质瘤中的抗药机制及长期应答特征

2025-11-010
PRE
Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies

CD22 CAR T细胞在B-ALL中的治疗效果:两种制造策略的故事

2025-10-020
PRE
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas

静脉和颅内GD2-CAR T细胞用于H3K27M弥漫性中线胶质瘤

Nature
IF48.5
2024-11-130
OA
MYELOID POPULATIONS MODULATE GD2 CAR T CELL ACTIVITY IN DIFFUSE MIDLINE GLIOMA
2024-11-110
PRE
Case report: sub-clinical extramedullary B-ALL in the setting of relapse following targeted therapy

病例报告: 靶向治疗后复发的亚临床髓外b-all

2024-09-250
OAAI
TUMOR INFLAMMATION-ASSOCIATED NEUROTOXICITY (TIAN): A TOXICITY SYNDROME IN PATIENTS TREATED WITH IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS

肿瘤炎症相关神经毒性 (TIAN): 中枢神经系统肿瘤免疫治疗患者的毒性综合征

2024-06-180
OAAI
SEQUENTIAL INTRAVENOUS AND INTRACEREBROVENTRICULAR GD2-CAR T-CELL THERAPY FOR H3K27M-MUTATED DIFFUSE MIDLINE GLIOMAS
2024-06-180
OAAI
Investigating the role of CXCR3+monocytes on CAR T cell function
2024-03-220
PRE
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results
LEUKEMIA
IF13.4
2024-03-153
OA
INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studies-Established Findings and Future Priorities

启发研讨会第4B部分: 嵌合抗原受体T细胞相关研究-已确定的发现和未来的优先事项

2024-02-012
PRE
TUMOR INFLAMMATION-ASSOCIATED NEUROTOXICITY (TIAN): A TOXICITY SYNDROME IN PATIENTS TREATED WITH IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS
2023-06-120
OAAI
Tumor inflammation-associated neurotoxicity

肿瘤炎症相关神经毒性

2023-04-0647
OA
Immune signatures of GD2 CAR T cell activity in H3K27M+diffuse midline glioma patients
2023-04-040
PRE